A phase 1 randomized, placebo-controlled, single ascending dose study to examine the safety, tolerability, and pharmacokinetics of CNP8 in healthy adults

Active Project Grant Awarded Last action

Award ID
HT94252311064
Recipient
Awarding agency
Obligated
$2,199,979

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date 79% complete
Originally
Place of performance
Stony Brook, NY 11790, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $0
Original award $2,199,979

Quick answers

Who received award HT94252311064?

HT94252311064 was awarded to Neomatrix Therapeutics Inc. by Defense Health Agency (Department of Defense) on September 22, 2023.

How much is award HT94252311064 worth?

$2,199,979 has been obligated on HT94252311064.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award